<DOC>
	<DOC>NCT00639808</DOC>
	<brief_summary>The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.</brief_summary>
	<brief_title>Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Subject has type 1 or type 2 diabetes mellitus Subject has documented diagnosis of gastroparesis by: Delayed gastric emptying (gastric retention ≥60% at 2h and ≥10% at 4 h; based on scintigraphy 4h standardized radionuclide solid meal) A minimum 3 month history of chronic upper abdominal discomfort (two or more: chronic postprandial fullness, bloating, epigastric discomfort, early satiety, belching after meal, postprandial nausea, vomiting) Subject has normal upper endoscopy If female, must be permanently sterilized or postmenopausa. Patient has received any investigational drug within the preceding 30 days Patient is taking unstable doses of medication that affects gastric motility Patient has comorbid condition Patient has a positive laboratory test result for hepatitis B, hepatitis C, HIV, or controlled substances. Patient has a history of a psychiatric disorder (including drug or alcohol addiction) requiring care by a psychiatrist or psychologist within the preceding 12 months. Patient has a recent,adult history of clinically significanthypersensitivity reaction(s) to any drug. Patient has known history of alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>delayed gastric emptying</keyword>
	<keyword>symptomatic gastroparesis</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>